Duotide25 mcg+62.5 mcg

Duotide is a combination of a long-acting beta2-adrenergic agonist (LABA) and a long-acting muscarinic antagonist (LAMA) delivered as a once-daily dry powder inhalation.

Established / FDA-approved use

• Long-term, once-daily maintenance treatment of airflow obstruction in chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema, in adult patients.

Important limitations

• Duotide is not indicated for asthma. Safety and efficacy in asthma have not been established, and combination LABA/LAMA therapy should not substitute for asthma-specific treatment in patients who have asthma rather than COPD.
• Duotide is not a rescue inhaler and must not be used for the acute relief of sudden breathlessness or acute bronchospasm; a short-acting bronchodilator should be used for acute symptoms.

Duotide is not approved or recommended for use in children.

Each single inhalation of Vilanterol Trifenatate + Umeclidinium Bromide dry powder for oral inhalation delivers:

• Vilanterol (as vilanterol trifenatate) 25 mcg
• Umeclidinium (as umeclidinium bromide) 62.5 mcg

The powder blend is delivered from a multi-dose, foil-sealed inhalation device and contains lactose monohydrate (which may contain trace milk proteins) as a carrier.

Duotide is a fixed-dose combination inhaled medicine used in the long-term maintenance treatment of chronic obstructive pulmonary disease (COPD). It combines two complementary bronchodilator mechanisms in a single once-daily dry powder inhaler: vilanterol trifenatate, a long-acting beta2-adrenergic agonist (LABA), and umeclidinium bromide, a long-acting muscarinic antagonist (LAMA, also called an anticholinergic).

By combining a LABA and a LAMA, Duotide produces greater and more sustained bronchodilation than either component alone, helping to reduce airflow obstruction, breathlessness, and COPD exacerbations when used regularly as prescribed. It is intended for chronic, everyday maintenance use and is not a treatment for acute bronchospasm or asthma.

Duotide belongs to the therapeutic class of combination inhaled bronchodilators for COPD, specifically a Long-Acting Beta2-Agonist (LABA) + Long-Acting Muscarinic Antagonist (LAMA) combination.

Vilanterol Trifenatate + Umeclidinium Bromide combines two bronchodilator drug classes with complementary mechanisms of action on airway smooth muscle:

• Vilanterol trifenatate (LABA): selectively stimulates beta2-adrenergic receptors on bronchial smooth muscle, activating adenylyl cyclase and increasing intracellular cyclic AMP (cAMP). This leads to relaxation of bronchial smooth muscle and bronchodilation that lasts approximately 24 hours, supporting once-daily dosing.
• Umeclidinium bromide (LAMA): competitively and reversibly inhibits the action of acetylcholine at M3 muscarinic receptors on airway smooth muscle, blocking cholinergically-mediated bronchoconstriction and producing sustained, once-daily bronchodilation.

Together, the two components act on distinct receptor pathways to produce additive improvement in lung function (FEV1) compared with either agent used alone.

Duotide is supplied as a dry powder inhaler and should be used exactly as follows:

• Take one inhalation by mouth, once daily, at the same time every day, to maintain steady bronchodilator effect.
• Do not use a spacer device with Duotide.
• Keep the inhaler dry; open the cover only immediately before use and close it fully after each dose.
• Do not exhale into the mouthpiece.
• If a dose is missed, take it as soon as remembered but do not take two doses at the same time.
• Duotide is not for acute relief of breathing problems; a fast-acting rescue inhaler should be used for sudden symptoms.

The following interactions with Duotide are clinically significant and well documented:

• Other anticholinergic (antimuscarinic) medicines: Concomitant use with other LAMA-containing or anticholinergic drugs is not recommended, as it may increase the risk of anticholinergic adverse effects (e.g., dry mouth, urinary retention, constipation).
• Other LABA-containing medicines or adrenergic agonists: Concomitant use with other medicines containing a LABA, or other adrenergic agents, is not recommended due to the risk of additive cardiovascular effects.
• Non-selective beta-blockers: May reduce the bronchodilator effect of Duotide and can, in some patients, provoke bronchospasm; if a beta-blocker is required, a cardioselective agent should be considered and the patient monitored.
• Monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants: May potentiate the cardiovascular effects (e.g., QT prolongation, tachycardia) of the beta-agonist component; use Duotide with caution in patients taking these agents or within 2 weeks of stopping them.
• Strong CYP3A4/P-glycoprotein inhibitors (e.g., ketoconazole): May increase systemic exposure to vilanterol; use with caution, monitoring for cardiovascular adverse effects.
• Non-potassium-sparing diuretics (e.g., loop or thiazide diuretics): ECG changes and/or hypokalemia associated with beta-agonists may be worsened; consider using with caution and monitor potassium levels.

The most commonly reported side effects of Duotide include:

• Nasopharyngitis (common cold-like symptoms) and upper respiratory tract infection
• Cough and oropharyngeal pain
• Bronchitis and sinusitis
• Dry mouth
• Constipation and diarrhea
• Back pain and muscle spasms
• Headache

Less common but more serious effects (e.g., paradoxical bronchospasm, cardiovascular effects, urinary retention, worsening of narrow-angle glaucoma, hypersensitivity reactions) are described in detail under Precautions and Warnings.

Pregnancy: There is limited human data on the use of Duotide in pregnant women. Animal reproduction studies with its individual components have shown effects only at exposures well above the recommended human dose. Duotide should be used during pregnancy only if the potential benefit to the mother (e.g., control of COPD symptoms and prevention of exacerbations) justifies the potential risk to the fetus, and only under the guidance of a physician. Uncontrolled COPD itself poses risks to both mother and fetus, so treatment is generally continued when clinically needed.

Lactation: It is not known whether the components of Duotide pass into human breast milk. A decision should be made whether to discontinue breastfeeding or discontinue the medicine, taking into account the benefit of breastfeeding and the mother's clinical need for Duotide, in consultation with a physician.

• Not for acute symptoms: Duotide is a maintenance treatment and must not be used to treat acute episodes of breathlessness or bronchospasm; a short-acting rescue bronchodilator should be used for acute symptoms.
• Not for asthma: Duotide has not been studied in asthma and is not indicated for its treatment.
• Paradoxical bronchospasm: As with other inhaled bronchodilators, Duotide can rarely cause paradoxical bronchospasm; discontinue immediately and treat with an alternative bronchodilator if this occurs.
• Cardiovascular effects: The beta-agonist component can produce clinically significant cardiovascular effects (tachycardia, palpitations, arrhythmias, and rarely elevations in blood pressure); use with caution in patients with cardiovascular disease, especially coronary insufficiency, arrhythmias, and hypertension.
• Urinary retention: Due to its anticholinergic activity, Duotide should be used with caution in patients with symptomatic benign prostatic hyperplasia, bladder-neck obstruction, or urinary retention, as it may worsen these conditions.
• Worsening of narrow-angle glaucoma: Use with caution in patients with narrow-angle glaucoma; instruct patients to seek prompt medical care if they develop eye pain, blurred vision, or visual halos.
• Hypersensitivity reactions: Immediate hypersensitivity reactions, including anaphylaxis, angioedema, rash, and urticaria, have been reported; discontinue Duotide if these occur.
• Do not exceed the recommended dose of one inhalation once daily.

Overdose with Duotide would be expected to produce exaggerated effects of its two components, such as tachycardia, palpitations, tremor, headache, hyperglycemia, and hypokalemia (from the beta-agonist component), together with dry mouth, blurred vision, urinary retention, and constipation (from the anticholinergic component).

There is no specific antidote for overdose with Duotide. If overdose is suspected, seek immediate medical attention or contact emergency services/poison control; management is supportive, with cardiac monitoring and correction of electrolyte disturbances as clinically indicated.

Store at room temperature (below 30°C), away from light and moisture. Keep the inhaler inside its sealed tray until first use, and discard it 6 weeks after opening the tray or when the dose counter reaches zero, whichever comes first. Keep the mouthpiece cover closed when not in use, and keep out of reach of children.

• Elderly: No dose adjustment is generally required, but elderly patients should be monitored closely given a higher likelihood of cardiovascular comorbidities and concomitant medications.
• Renal impairment: No dose adjustment needed in mild-to-moderate impairment; use with caution in severe renal impairment or end-stage renal disease.
• Hepatic impairment: No dose adjustment needed in mild-to-moderate impairment; use with caution in severe hepatic impairment, as it has not been studied.
• Pediatric use: Duotide is not indicated for use in patients under 18 years of age; safety and efficacy have not been established in this population.

Duotide is intended for long-term, chronic, once-daily maintenance treatment of COPD and should be used continuously as prescribed, even when the patient feels well, to maintain control of airflow obstruction. It is not intended for short-term or as-needed (PRN) use. Duration of treatment should be reviewed periodically by the prescribing physician based on ongoing clinical response.

Vilanterol Trifenatate + Umeclidinium Bromide belongs to the following drug classes:

• Long-Acting Beta2-Adrenergic Agonist (LABA) — vilanterol trifenatate component
• Long-Acting Muscarinic Antagonist (LAMA) / anticholinergic bronchodilator — umeclidinium bromide component
• Combination inhaled bronchodilator for COPD (LABA/LAMA combination)

Vilanterol Trifenatate + Umeclidinium Bromide works through two complementary bronchodilator mechanisms delivered together: vilanterol stimulates beta2-adrenergic receptors in airway smooth muscle to raise intracellular cAMP and relax the muscle, while umeclidinium blocks acetylcholine at M3 muscarinic receptors to prevent cholinergically mediated bronchoconstriction. The combined effect produces greater, more sustained once-daily bronchodilation in COPD than either mechanism alone.

Duotide is not approved for use in children or adolescents. Safety and efficacy in patients under 18 years of age have not been established, and Duotide is not indicated for asthma, which is the predominant obstructive airway disease seen in the pediatric population. Duotide should not be prescribed to pediatric patients outside of the approved adult COPD indication.